Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses various hair growth treatments, including topical and oral minoxidil, microneedling, LLLT, PRP, exosomes, latanoprost, copper peptides, and upcoming treatments like PP405 and Vdphl01. It also covers managing side effects of minoxidil, such as dry scalp, and mentions the use of dutasteride and finasteride for hair loss.

A 40+ year old is regrowing their hairline using microneedling, minoxidil, tretinoin, low-level laser therapy, massages, and Nizoral, without using finasteride or dutasteride. They noted progress in hair growth below a birthmark, an area that hadn't seen growth since their teenage years.

The user shared their 7.5-month post-hair transplant results, mentioning they have been using finasteride and oral minoxidil. The conversation includes mixed reactions, with some users complimenting the results and others critiquing the hairstyle and presentation.

A user shared their 1.5-year progress after a FUE crown transplant, using dutasteride and oral minoxidil, which improved their hairline and stabilized hair loss. They experienced dizziness from topical minoxidil but had no side effects from finasteride, dutasteride, or oral minoxidil.

OP is using 5% minoxidil and a needler to regrow hair after chemotherapy-induced hair loss. Another user mentions using finasteride and topical minoxidil, noting some improvement in hair density.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation is about people with advanced hair loss (Norwood 6 or 7) who have seen significant hair regrowth using treatments like finasteride, minoxidil, microneedling, and RU58841. Nine cases were collected to motivate others to try these treatments despite advanced hair loss.

The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The user has been using 3mg oral Minoxidil and 1.1mg oral Finasteride for 15 months and plans to switch to 5mg oral Minoxidil, 1.1mg oral Finasteride, and 0.1mg oral Dutasteride. They have also used ketoconazole and salicylic acid shampoo for seborrheic dermatitis and hope to see more hair growth with the increased dosage.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A 29-year-old is using 5% topical minoxidil, 5 mg oral minoxidil, 1 mg finasteride, Nizoral shampoo, and weekly microneedling to treat hair loss, reporting significant progress in hair regrowth and hairline improvement. The routine includes applying minoxidil twice daily, managing dead skin with shampoo, and using a baseball cap to maintain hair appearance.

A 51-year-old shared progress on hair regrowth using topical Minoxidil and Finasteride over four months, noting significant improvement and plans for future hair transplants. The user emphasized the benefits of modern treatments and societal changes in attitudes towards hair loss.

A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.

A user shared a 10-month update on their hair loss treatment, including a hair transplant of 2300 grafts and 7.5 months of using a topical minoxidil/finasteride solution and ketoconazole shampoo. They expressed regret for not starting the medications sooner and reported side effects like heart palpitations, which improved after cutting out caffeine.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

The user experienced hairline improvement using microneedling once a month with a 12-pin set at 1.5-2.0mm and taking Tru Niagen, alongside a heavily modified diet. They attribute the slow hairline improvement to environmental factors, particularly diet, rather than solely genetic factors.

The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.

Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Hair loss discussion with a focus on a single resilient hair, jokingly called "chad hair," that remains despite hairline receding. Some users suggest microneedling and hair follicle cloning as potential treatments.

The user has been using minoxidil and finasteride for 7.5 months to address hair thinning, particularly at the crown and temples, and is considering additional treatments like tretinoin and dermastamping despite having chronic scalp folliculitis. They are experiencing progress but are concerned about side effects and the effectiveness of treatments on temple regrowth.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.

The user underwent a hair transplant in Turkey and has been using a topical solution with 5% minoxidil and 0.0025% finasteride, along with Ket 2% shampoo and derma rolling, to maintain hair status. They are uncertain about improvements, noting thicker non-transplanted hair, and are considering increasing medication frequency to enhance results.